US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a...
from NDTV News - Special https://ift.tt/36lyTbO
via IFTTT
Thursday, 28 January 2021
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment